Overview

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib